Cited by 365Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer ResearchRadiopharmaceutical Chemistry and Applications

The DOI matches its Crossref record; 27 of the 33 references it cites were found in a registry or an index.

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

Open access

Rudnick, Stephen I., Lou, Jianlong, Shaller, Calvin C., Tang, Yong, Klein-Szanto, Andres J.P., Weiner, Louis M., Marks, James D., Adams, Gregory P.·2011·Cancer Research

DOI 10.1158/0008-5472.can-10-2277PMC PMC3077882

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Antibody drugs are widely used in cancer therapy, but conditions to maximize tumor penetration and efficacy have yet to be fully elucidated. In this study, we investigated the impact of antibody binding affinity on tumor targeting and penetration with affinity variants that recognize the same epitope. Specifically, we compared four derivatives of the C6.5 monoclonal antibody (mAb), which recognizes the same HER2 epitope (monovalent KD values ranging from 270 to 0.56 nmol/L). Moderate affinity was associated with the highest tumor accumulation at 24 and 120 hours after intravenous injection, whereas high affinity was found to produce the lowest tumor accumulation. Highest affinity mAbs were confined to the perivascular space of tumors with an average penetration of 20.4 ± 7.5 μm from tumor blood vessels. Conversely, lowest affinity mAbs exhibited a broader distribution pattern with an average penetration of 84.8 ± 12.8 μm. In vitro internalization assays revealed that antibody internalization and catabolism generally increased with affinity, plateauing once the rate of HER2 internalization exceeded the rate of antibody dissociation. Effects of internalization and catabolism on tumor targeting were further examined using antibodies of moderate (C6.5) or high-affinity (trastuzumab), labeled with residualizing (111In-labeled) or nonresidualizing (125I-labeled) radioisotopes. Significant amounts of antibody of both affinities were degraded by tumors in vivo. Furthermore, moderate- to high-affinity mAbs targeting the same HER2 epitope with monovalent affinity above 23 nmol/L had equal tumor accumulation of residualizing radiolabel over 120 hours. Results indicated equal tumor exposure, suggesting that mAb penetration and retention in tumors reflected affinity-based differences in tumor catabolism. Together, these results suggest that high-density, rapidly internalizing antigens subject high-affinity antibodies to greater internalization and degradation, thereby limiting their penetration of tumors. In contrast, lower-affinity antibodies penetrate tumors more effectively when rates of antibody–antigen dissociation are higher than those of antigen internalization. Together, our findings offer insights into how to optimize the ability of therapeutic antibodies to penetrate tumors. Cancer Res; 71(6); 2250–9. ©2011 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-10-2277

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 642
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 623
Self-citation
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
Jain, R. K. (1990) · PubMed · Cited by 574
Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin
Austin, C. D., Mazière, A. M. G. L. D., Pisacane, P. I., van Dijk, S., Eigenbrot, C. W., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 507
Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site
Schier, R., McCall, A. M., Adams, G. P., Marshall, K. W., Merritt, H., Yim, M., Crawford, R. S., Weiner, L. M., Marks, C. B., & Marks, J. D. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0598 · Cited by 382
Self-citation
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 356
Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using Affinity-driven Selection
Schier, R., Bye, J. M., Apell, G., McCall, A. M., Adams, G. P., Malmqvist, M., Weiner, L. M., & Marks, J. D. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0004 · Cited by 291
Self-citation
Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1989) · PubMed · Cited by 258
Efficient Tumor Targeting with High-Affinity Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular Size
Zahnd, C., Kawe, M., Stumpp, M. T., de Pasquale, C., Tamaskovic, R., Nagy‐Davidescu, G., Dreier, B., Schibli, R., Binz, H. K., Waibel, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2724 · Cited by 245
Affinity and Avidity in Antibody-Based Tumor Targeting
Rudnick, S. I., & Adams, G. P. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0627 · Cited by 237
Self-citation

Show all 33 references

Research works printed but not linked: 1

Adams, 1992, Comparison of the pharmacokinetics in mice and the biological-activity of murine L6 and human-mouse chimeric Ch-L6 antibody, Antib Immunoconjug Radiopharm, 5, 81

Sorted by citations

Items 101–200 of 365

Hepatocellular carcinoma-targeted nanoparticles for cancer therapy
Wu, C., Lan, C.-H., Wu, K., Wu, Y., Jane, W., Hsiao, M., & Wu, H. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4205 · Cited by 46
A dynamic magnetic shift method to increase nanoparticle concentration in cancer metastases: a feasibility study using simulations on autopsy specimens
Nacev, A. N., Kim, Rodriguez‐Canales, J., Tangrea, Shapiro, & Emmert-Buck (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s23724 · Cited by 46
Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection
Sadekar, S., Figueroa, I., & Tabrizi, M. A. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9766-0 · Cited by 45
The Effect of Molecular Weight, PK, and Valency on Tumor Biodistribution and Efficacy of Antibody-Based Drugs
Muchekehu, R., Liu, D., Horn, M., Campbell, L. A., Rosario, J. D., Bacica, M., Moskowitz, H., Osothprarop, T., Dirksen, A., Doppalapudi, V. R., et al. (2013) · Translational Oncology · doi:10.1593/tlo.13409 · Cited by 43
Antibody drug conjugates: Progress, pitfalls, and promises
Mukherjee, A., Waters, A. K., Babić, I., Nurmemmedov, E., Glassy, M. C., Kesari, S., & Yenugonda, V. M. (2018) · Human Antibodies · doi:10.3233/hab-180348 · Cited by 43
Assessments of antibody biodistribution
Glassman, P. M., Abuqayyas, L., & Balthasar, J. P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.365 · Cited by 42
Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
Zhang, H., Wang, Y., Wu, Y., Jiang, X., Tao, Y., Yao, Y., Peng, Y., Chen, X., Fu, Y., Yu, L., et al. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.15 · Cited by 43
Quantitative Measurement of the Target-Mediated Internalization Kinetics of Biopharmaceuticals
Vainshtein, I., Roskos, L. K., Cheng, J. C., Sleeman, M. A., Wang, B., & Liang, M. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1462-8 · Cited by 41
Quantitative Assessment of Antibody Internalization with Novel Monoclonal Antibodies against Alexa Fluorophores
Liao-Chan, S., Daine-Matsuoka, B., Heald, N., Wong, T., Lin, T., Cai, A. G., Lai, M., D’Alessio, J. A., & Theunissen, J.-W. F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124708 · Cited by 41
Pharmacokinetics of Bispecific Antibody
Chen, Y., & Xu, Y. C. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0090-5 · Cited by 40
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
Cheal, S. M., Xu, H., Guo, H.-F., Patel, M., Punzalan, B. J., Fung, E. K., Lee, S., Bell, M. M., Singh, M., Jungbluth, A. A., et al. (2018) · Theranostics · doi:10.7150/thno.26585 · Cited by 41
Selecting an Optimal Antibody for Antibody–Drug Conjugate Therapy: Internalization and Intracellular Localization
Harper, J. W., Mao, S., Strout, P., & Kamal, A. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_3 · Cited by 39
A Liposomal Drug Platform Overrides Peptide Ligand Targeting to a Cancer Biomarker, Irrespective of Ligand Affinity or Density
Gray, B. P., McGuire, M. J., & Brown, K. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072938 · Cited by 39
High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe
Riedl, T., van Boxtel, E., Bosch, M., Parren, P. W. H. I., & Gerritsen, A. F. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115613270 · Cited by 39
Aptamer-mediated doxorubicin delivery reduces HCC burden in 3D organoids model
Zhou, K. L., Huo, X., Nguyen, R., Bae, S. D. W., Han, S., Zhang, Z., Duan, W., Yuen, L., Lam, V. W. T., George, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.036 · Cited by 38
Rational nanocarrier design towards clinical translation of cancer nanotherapy
Guo, D., Ji, X., & Luo, J. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe35a · Cited by 39
A Nano “Immune‐Guide” Recruiting Lymphocytes and Modulating the Ratio of Macrophages from Different Origins to Enhance Cancer Immunotherapy
Sun, W., Yang, J., Hou, M., Xie, S., Xiong, L., Li, B., & Zhang, C. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009116 · Cited by 39
Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions
Tang, Y., & Cao, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030422 · Cited by 42
Self-citation
Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET
Ikotun, O. F., Marquez-Nostra, B. V., Huang, C., Masuko, K., Daiji, M., Masuko, T., McConathy, J., & Lapi, S. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077476 · Cited by 37
High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1
Opaliński, Ł., Szymczyk, J., Sochacka, M., Kucińska, M. K., Krowarsch, D., Zakrzewska, M., & Otlewski, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051435 · Cited by 35
FRET Reagent Reveals the Intracellular Processing of Peptide-Linked Antibody–Drug Conjugates
Lee, B.-C., Chalouni, C. M., Doll, S., Nalle, S. C., Darwish, M., Tsai, S. P., Kozak, K. R., Del-Rosario, G., Yu, S., Erickson, H. K., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00362 · Cited by 35
T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
Kamakura, D., Asano, R., & Yasunaga, M. (2021) · Pharmaceuticals · doi:10.3390/ph14111172 · Cited by 37
Nanotechnology-based delivery systems to overcome drug resistance in cancer
Patel, H. H., Li, J., Bo, L., Mehta, R., Ashby, C. R., Wang, S., Cai, W., & Chen, Z. (2024) · Medical Review · doi:10.1515/mr-2023-0058 · Cited by 38
Quantitative diagnosis of HER 2 protein expressing breast cancer by single‐particle quantum dot imaging
Miyashita, M., Gonda, K., Tada, H., Watanabe, M., Kitamura, N., Kamei, T., Sasano, H., Ishida, T., & Ohuchi, N. (2016) · Cancer Medicine · doi:10.1002/cam4.898 · Cited by 34
Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
Wang, Y.-J., Li, Y., Liu, X., Lu, X., Cao, X., & Jiao, B. (2017) · Marine Drugs · doi:10.3390/md15010018 · Cited by 34
A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency
Rezaie, E., Amani, J., Pour, A. B., & Hosseini, H. M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172912 · Cited by 34
Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective
Dahlgren, D., & Lennernäs, H. (2020) · Molecules · doi:10.3390/molecules25122861 · Cited by 34
Production process reproducibility and product quality consistency of transient gene expression in HEK293 cells with anti-PD1 antibody as the model protein
Ding, K., Han, L., Zong, H., Chen, J., Zhang, B., & Zhu, J. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7973-y · Cited by 34
Molecular tumor targeting of gelonin by fusion with F3 peptide
Ham, S., Min, K. A., & Shin, M. C. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.20 · Cited by 34
Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer
Harrington, B. S., He, Y., Khan, T., Puttick, S. G., Conroy, P. J., Kryza, T., Cuda, T., Sokolowski, K. A., Tse, B. W.-C., Robbins, K. K., et al. (2020) · Theranostics · doi:10.7150/thno.30736 · Cited by 31
Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation
McComb, S., Nguyen, T., Shepherd, A., Henry, K. A., Bloemberg, D., Marcil, A., MacLean, S., Zafer, A., Gilbert, R., Gadoury, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864868 · Cited by 31
IgG Fc Affinity Ligands and Their Applications in Antibody-Involved Drug Delivery: A Brief Review
Yang, C., He, B., Zhang, H., Wang, X., Zhang, Q., & Dai, W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010187 · Cited by 31
Anti-Tumor Effect of Parasitic Protozoans
Ding, H., Wu, S., Jin, Z., Zheng, B., Hu, Y., He, K., Lu, S., & Zhuo, X. (2022) · Bioengineering · doi:10.3390/bioengineering9080395 · Cited by 31
Multichannel Imaging to Quantify Four Classes of Pharmacokinetic Distribution in Tumors
Bhatnagar, S., Deschenes, E., Liao, J., Cilliers, C., & Thurber, G. M. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24086 · Cited by 30
Quantitative Comparison of Tumor Delivery for Multiple Targeted Nanoparticles Simultaneously by Multiplex ICP-MS
Elias, A., Crayton, S. H., Warden‐Rothman, R., & Tsourkas, A. (2014) · Scientific Reports · doi:10.1038/srep05840 · Cited by 30
Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance
Tibbetts, R., Yeo, K. K., Muthugounder, S., Lee, M.-H., Jung, C., Porras-Corredor, T., Sheard, M. A., & Asgharzadeh, S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02963-y · Cited by 31
Recombinant TAT-gelonin fusion toxin: Synthesis and characterization of heparin/protamine-regulated cell transduction
Shin, M. C., Zhao, J., Zhang, J., Huang, Y., He, H., Wang, M., Min, K. A., & Yang, V. C.-M. (2014) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35188 · Cited by 29
Targeted nanoparticles for simultaneous delivery of chemotherapeutic and hyperthermia agents – An in vitro study
Srinivasan, S., Manchanda, R., Lei, T., Nagesetti, A., Fernandez-Fernandez, A., & McGoron, A. J. (2014) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2014.04.012 · Cited by 29
Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting
Geddie, M. L., Kohli, N., Kirpotin, D. B., Razlog, M., Jiao, Y., Kornaga, T., Rennard, R., Xu, L., Schoerberl, B., Marks, J. D., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1259047 · Cited by 29
Self-citation
RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models
Wong, O. K., Tran, T.-T., Ho, W.-H., Casas, M. G., Au, M., Bateman, M. E., Lindquist, K. C., Rajpal, A., Shelton, D. L., Strop, P., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26002 · Cited by 30
Molecular platforms for targeted drug delivery
Maso, K., Grigoletto, A., Vicent, M. J., & Pasut, G. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.03.001 · Cited by 30
AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
Weng, W., Meng, T., Pu, J., Ma, L., Shen, Y., Wang, Z., Pan, R., Wang, M., Chen, C., Wang, L., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0198 · Cited by 28
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
Domı́nguez, J. M., Pérez-Chacón, G., Guillén, M. J., Muñoz-Alonso, M. J., Somovilla-Crespo, B., Cibrián, D., Acosta‐Iborra, B., Adrados, M., Muñoz‐Calleja, C., Cuevas, C., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00865-7 · Cited by 27
Development of Peptide Paratope Mimics Derived from the Anti-ROR1 Antibody and Long-Acting Peptide–Drug Conjugates for Targeted Cancer Therapy
Zhang, Y., Fan, Y., Liu, S., Guan, Y., Wan, J., Ren, Q., Wang, J., Zhong, L., Hu, Z., Shi, W., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00511 · Cited by 26
Peptide-targeted nanoparticles for tumor therapy
Sidorenko, V., Tobi, A., Sugahara, K. N., & Teesalu, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114195 · Cited by 26
Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen
Sedlik, C., Heitzmann, A., Viel, S., Sarkouh, R. A., Batisse, C., Schmidt, F., Rochère, P. D. L., Amzallag, N., Osinaga, E., Oppezzo, P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1171434 · Cited by 26
Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging
Orcutt, K. D., Adams, G. P., Wu, A. M., Silva, M. D., Harwell, C., Hoppin, J., Matsumura, M., Kotsuma, M., Greenberg, J., Scott, A. M., et al. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1041-y · Cited by 26
Self-citation
Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells
Hellmann, I., Waldmeier, L., Bannwarth-Escher, M.-C., Maslova, K., Wolter, F. I., Grawunder, U., & Beerli, R. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02490 · Cited by 26
High-content Analysis of Antibody Phage-display Library Selection Outputs Identifies Tumor Selective Macropinocytosis-dependent Rapidly Internalizing Antibodies
Ha, K. D., Bidlingmaier, S. M., Zhang, Y., Yang, S., & Liu, B. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.039768 · Cited by 25
Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier
Ruoslahti, E. I. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93955 · Cited by 25
Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes
Chen, I., Cheng, Y., Ho, K., Lin, W.-W., Cheng, K.-W., Lu, Y., Hsieh, Y.-C., Huang, C.-C., Chuang, C.-H., Chen, F., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.04.029 · Cited by 25
Improving drug penetration to curb tumor drug resistance
Marcucci, F., & Corti, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.06.004 · Cited by 26
Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
Mason‐Osann, E., Hollevoet, K., Niederfellner, G. J., & Pastan, I. H. (2015) · Scientific Reports · doi:10.1038/srep10832 · Cited by 24
Antibody-drug conjugate and free geldanamycin combination therapy enhances anti-cancer efficacy
McCombs, J. R., Chang, H., Shah, D. K., & Owen, S. C. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121272 · Cited by 24
Targeting Phosphatidylserine with Calcium-Dependent Protein–Drug Conjugates for the Treatment of Cancer
Li, R., Chiguru, S., Li, L., Kim, D., Velmurugan, R., Kim, D., Devanaboyina, S. C., Tian, H., Schroit, A. J., Mason, R. P., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0092 · Cited by 24
Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy
Zhou, X., Han, Y., Fang, Y., Ma, P., Zhou, J., Jiang, Y., Xing, S., Tang, Q., Hou, Y., Wang, S., et al. (2025) · Med · doi:10.1016/j.medj.2025.100849 · Cited by 26
Entwicklung zielgerichteter niedermolekularer zytotoxischer Wirkstoffverbindungen mit DNA‐codierten chemischen Bibliotheken
Krall, N., Scheuermann, J., & Neri, D. (2013) · Angewandte Chemie · doi:10.1002/ange.201204631 · Cited by 23
The Interplay of Antigen Affinity, Internalization, and Pharmacokinetics on CD44-Positive Tumor Targeting of Monoclonal Antibodies
Glatt, D. M., Beckford-Vera, D., Parrott, M. C., Luft, J. C., Benhabbour, S. R., & Mumper, R. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00063 · Cited by 23
IBC’s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA
Nilvebrant, J., Dunlop, D. C., Sircar, A., Wurch, T., Falkowska, E., Reichert, J. M., Helguera, G. F., Piccione, E. C., Brack, S., & Berger, S. (2012) · mAbs · doi:10.4161/mabs.4.2.19495 · Cited by 23
Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer
Shapiro, M. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1379738 · Cited by 22
A Binding-Site Barrier Affects Imaging Efficiency of High Affinity Amyloid-Reactive Peptide Radiotracers In Vivo
Wall, J. S., Williams, A. D., Richey, T., Stuckey, A. C., Huang, Y., Wooliver, C., Macy, S. D., Heidel, R. E., Gupta, N. A. D., Lee, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066181 · Cited by 22
Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling
Tiwari, A., Abraham, A. K., Harrold, J. M., Zutshi, A., & Singh, P. (2016) · The AAPS Journal · doi:10.1208/s12248-016-0004-1 · Cited by 22
Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model
Li, X., Jusko, W. J., & Cao, Y. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.250134 · Cited by 22
The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells
Poźniak, M., Porębska, N., Krzyścik, M. A., Sokołowska-Wędzina, A., Jastrzębski, K., Sochacka, M., Szymczyk, J., Zakrzewska, M., Otlewski, J., & Opaliński, Ł. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00306-2 · Cited by 22
Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment
Paulus, J., & Sewald, N. (2024) · Journal of Peptide Science · doi:10.1002/psc.3561 · Cited by 24
Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses
Zhang, B., Zhang, Z., Gao, J., Lu, S., Pang, R., Li, D., Huang, X., Qin, N., Liu, L., & Wang, Z. (2024) · iScience · doi:10.1016/j.isci.2024.111536 · Cited by 24
Aptamer-functionalized liposomes for targeted cancer therapy
Moosavian, S. A., Kesharwani, P., Singh, V., & Sahebkar, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85881-6.00014-2 · Cited by 21
Antigen-responsive molecular sensor enables real-time tumor-specific imaging
Kim, H., Choi, H. S., Kim, S.-K., Lee, B. I., & Choi, Y. (2017) · Theranostics · doi:10.7150/thno.16647 · Cited by 20
Strategies to boost antibody selectivity in oncology
Blay, V., & Pandiella, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.10.005 · Cited by 20
Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics
Kontermann, R. E., Ungerechts, G., & Nettelbeck, D. M. (2021) · mAbs · doi:10.1080/19420862.2021.1982447 · Cited by 19
Multi-Specific Antibodies for Cancer Immunotherapy
Jachimowicz, R. D., Borchmann, S., & Rothe, A. (2014) · BioDrugs · doi:10.1007/s40259-014-0091-4 · Cited by 20
Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions
Yu, J., Li, M., Liu, X., Wu, S., Li, R., Jiang, Y., Zheng, J., Li, Z., Xin, K., Xu, Z., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116522 · Cited by 22
Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates
Zwaagstra, J. C., Sulea, T. I., Baardsnes, J., Radinovic, S., Donates, Y. C., Robert, A., O'Connor‐McCourt, M. D., Tikhomirov, I. A., & Jaramillo, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226593 · Cited by 18
Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non‐Ig scaffolds
Warnders, F.-J., Hooge, M. N. L., de Vries, E. G. E., & Kosterink, J. G. W. (2018) · Medicinal Research Reviews · doi:10.1002/med.21498 · Cited by 20
IBC’s 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society
Klöhn, P., Wuellner, U., Zizlsperger, N., Zhou, Y., Tavares, D., Berger, S., Zettlitz, K. A., Proetzel, G., Yong, M., Beǵent, R. H. J., et al. (2013) · mAbs · doi:10.4161/mabs.23655 · Cited by 18
Advances in the pharmaceutical development of antibody-oligonucleotide conjugates
Li, M., An, H., Zhang, J., Li, W., Yu, C., & Wang, L. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107292 · Cited by 21
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response
Chuh, J., Go, M., Chen, Y., Guo, J., Rafidi, H., Mandikian, D., Sun, Y., Lin, Z., Schneider, K., Zhang, P., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1862452 · Cited by 17
Inhibition of Liver Metastasis in Colorectal Cancer by Targeting IL-13/IL13Rα2 Binding Site with Specific Monoclonal Antibodies
Jaén, M., Bartolomé, R. A., Aizpurúa, C., Martín‐Regalado, Á., Imbaud, J. I., & Casal, J. I. (2021) · Cancers · doi:10.3390/cancers13071731 · Cited by 17
CPPs to the Test: Effects on Binding, Uptake and Biodistribution of a Tumor Targeting Nanobody
Camps, E. C., van Lith, S. A. M., Frielink, C., Lankhof, J., Dijkgraaf, I., Gotthardt, M., & Brock, R. E. (2021) · Pharmaceuticals · doi:10.3390/ph14070602 · Cited by 16
Genetic delivery of an immuno RN ase by an oncolytic adenovirus enhances anticancer activity
Fernández‐Ulibarri, I., Hammer, K., Arndt, M. A. E., Kaufmann, J. K., Dorer, D. E., Engelhardt, S., Kontermann, R. E., Heß, J., Allgayer, H., Krauß, J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29258 · Cited by 17
Fabrication and evaluation of a γ-PGA-based self-assembly transferrin receptor-targeting anticancer drug carrier
Zhang, L., Zhu, X., Wu, S., Chen, Y., Tan, S., Liu, Y., Jiang, W., & Huang, J. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s181121 · Cited by 17
Quantitative intratumoural microdistribution and kinetics of 131I-huA33 antibody in patients with colorectal carcinoma
Ciprotti, M., Chong, G., Gan, H. K., Chan, A. T. �., Murone, C., MacGregor, D. P., Lee, F.-T., Johns, T. G., Heath, J. K., Ernst, M., et al. (2014) · EJNMMI Research · doi:10.1186/s13550-014-0022-x · Cited by 16
Design and fabrication of cell-targeted, dual drug-loaded nanoparticles with pH-controlled drug release and near-infrared light-induced photothermal effects
Weng, C., Yang, T.-A., & Li, Y.-K. (2020) · Materials & Design · doi:10.1016/j.matdes.2020.109230 · Cited by 16
Molecular Engineering of Surface Functional Groups Enabling Clinical Translation of Nanoparticle–Drug Conjugates
Wu, F., Gardinier, T. C., Turker, M. Z., Chen, F., Chen, P.-M., Venkatesan, A. M., Patel, V., Adams, G. P., Bradbury, M. S., Wiesner, U. B., et al. (2022) · Chemistry of Materials · doi:10.1021/acs.chemmater.1c04447 · Cited by 16
Self-citation
Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy
Jung, K., Yoo, S., Kim, J.-E., Kim, W., & Kim, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1034774 · Cited by 16
Rapid Evaluation of Antibody Fragment Endocytosis for Antibody Fragment–Drug Conjugates
Kim, E. G., Jeong, J., Lee, J., Jung, H., Kim, M. H., Zhao, Y., Yi, E. C., & Kim, K. M. (2020) · Biomolecules · doi:10.3390/biom10060955 · Cited by 16
Linker Optimization and Therapeutic Evaluation of Phosphatidylserine-Targeting Zinc Dipicolylamine-based Drug Conjugates
Liu, Y.-W., Chen, Y., Hsu, C., Chiu, T., Liu, K.-L., Lo, C., Fang, M., Huang, Y., Yeh, T., Pak, K. Y., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00173 · Cited by 15
Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics
Dong, S., Nessler, I., Kopp, A., Rubahamya, B., & Thurber, G. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.836925 · Cited by 14
Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling
Diermeier‐Daucher, S., Ortmann, O., Buchholz, S., & Brockhoff, G. (2012) · mAbs · doi:10.4161/mabs.21003 · Cited by 14
Factors Influencing the Delivery Efficiency of Cancer Nanomedicines
Ullah, R., Wazir, J., Khan, F. U., Diallo, M. T., Ihsan, A. U., Mikrani, R., Aquib, M., & Zhou, X. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01691-3 · Cited by 15
Aptamer Enables Consistent Maytansine Delivery through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy
Tan, Y. H., Peng, Y., Ai, L., Li, Y., Qu, Y.-X., Wang, D., Su, Y., Deng, T., Fu, T., Zhao, Z., et al. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00250 · Cited by 13
Identification of critical chemical modifications by size exclusion chromatography of stressed antibody-target complexes with competitive binding
Shi, L., Xiao, G., Dillon, T. M., McAuley, A., Ricci, M. S., & Bondarenko, P. V. (2021) · mAbs · doi:10.1080/19420862.2021.1887612 · Cited by 13
The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model
Örbom, A., Eriksson, S. E., Elgström, E., Ohlsson, T. G., Nilsson, R., Tennvall, J., & Strand, S. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.117028 · Cited by 13
Evaluation of a Pretargeting Strategy for Molecular Imaging of the Prostate Stem Cell Antigen with a Single Chain Antibody
Tienken, L., Drude, N., Schau, I., Winz, O., Temme, A., Weinhold, E. G., Mottaghy, F. M., & Morgenroth, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-22179-y · Cited by 13
Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model
Kuo, W.-Y., Lin, J.-J., Hsu, H.-J., Chen, H.-S., Yang, A., & Wu, C.-Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-32094-x · Cited by 13
Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging
Mandikian, D., Rafidi, H., Adhikari, P., Venkatraman, P., Nazarova, L. A., Fung, G., Figueroa, I., Ferl, G. Z., Ulufatu, S., Ho, J., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1521132 · Cited by 13
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives
Lauro, V. D., Rizzo, A., Tafuro, M., Fina, E., Martinelli, C., Calderaio, C., Rienzo, R. D., Pirolo, M., Fanizzi, A., Massafra, R., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103023 · Cited by 12
Dissecting the impact of target-binding kinetics of protein binders on tumor localization
Song, Y., Jeong, H., Kim, S., Ryu, Y., Baek, J., Kwon, J., Cho, H., Kim, K., & Lee, J. (2021) · iScience · doi:10.1016/j.isci.2021.102104 · Cited by 12
Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen
Plüss, L., Peissert, F., Elsayed, A., Rotta, G., Römer, J., Plaza, S. D., Villa, A., Puca, E., Luca, R. D., Oxenius, A., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2217964 · Cited by 11
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy
Bidkar, A. P., Peter, R., Wadhwa, A., Bobba, K. N., Bidlingmaier, S. M., Meher, N., Chou, J., Greenland, N., Dasari, C., Naik, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2850 · Cited by 12

Authors: Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P.
Affiliations: Fox Chase Cancer Center (US)
Authors' Affiliations: 1Developmental Therapeutics Program and 2Pathology Department, Fox Chase Cancer Center, Philadelphia, Pennsylvania; 3Department of Anesthesia, University of California, San Francisco, California; and 4Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Colombia
Corresponding author: Adams, Gregory P.
ORCID: Lou, Jianlong
Tang, Yong
Weiner, Louis M.
Marks, James D.
Adams, Gregory P.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2011-03-14
Volume: 71
Issue: 6
Pages: 2250-2259
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-10-2277
PMC: PMC3077882
OpenAlex: W2103364597
Cited by: 365
References: 33
Citations by year: 2026: 21 · 2025: 32 · 2024: 17 · 2023: 21 · 2022: 19 · 2021: 36 · 2020: 30 · 2019: 14 · 2018: 35 · 2017: 19 · 2016: 24 · 2015: 26 · 2014: 24 · 2013: 24 · 2012: 17
FWCI: 17.33
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Fox Chase Cancer Center
National Cancer Institute (R01-CA50633, R01CA118159, T32CA009035, R01CA050633)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords: anti-HER2 antibody, antibody affinity, tumor penetration, tumor targeting, antigen uptake, antibody internalization, antibody catabolism, tumor accumulation, trastuzumab, HER2, perivascular spaces, solid tumors
MeSH terms: Animals, Antibodies, Monoclonal, Antibody Affinity, Epitopes, Antigens, Neoplasm, Binding, Competitive, Endocytosis, Female, Humans, Immunoglobulin G, Immunohistochemistry, Indium Radioisotopes, Iodine Radioisotopes, Mutation, Neoplasm Transplantation, Ovarian Neoplasms, Time Factors, Tissue Distribution, Transplantation, Heterologous, Mice, SCID, Erb-b2 Receptor Tyrosine Kinases, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks